You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI

    SBC: Haplomics            Topic: NIMHD

    DESCRIPTION (provided by applicant): About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Among African American HA patients, the frequency of inhibitor formation ismuch higher; about 50%. Inhibitor patients are typically treated with bypassing agents. Bypassing agents are more expensive and less effective t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Discovery of novel small molecule analgesics

    SBC: Epigen Biosciences, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Peripheral nerve injury can lead to anomalous sensations referred to as neuropathic pain. Nerve injury may result from a variety of insults ranging from frank injury to the nerve though sectioning or compression, to chemotherapeutics and autoimmune conditions. Symptoms often include continuous burning pain and abnormal sensory sensations such as allodynia (pain ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Therapeutic Opportunity in Stroke

    SBC: Epigen Biosciences, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is a leading cause of death and disability in the USA, yet widely effective treatments remain elusive and, except for a lengthy program of rehabilitation, no effective treatment for cerebral ischemic stroke is available. Therefore, there s a critical need in new therapeutic approaches which can maximally preserve ischemic penumbra and facilitate functio ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Recyclable Magnetic Co/C Hybrid ROMP Reagents, Scavengers and Ligands

    SBC: MATERIA, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): This Fast Track Small Business Technology Transfer study between Materia, Inc. in Pasadena, CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant (1R42GM097896-03)which ends on March 30, 2014. Preliminary results serve as a solid foundation for this Fast Track submission entitled Development of Recyclable ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery, approaches that are cumbersome to apply. Consequently, we have considered the u ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government